Document Detail


Increased incidence of interstitial pneumonia by CHOP combined with rituximab.
MedLine Citation:
PMID:  18409079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several authors have reported interstitial pneumonia (IP) during rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, while others have encountered Pneumocystis jirovecii pneumonia during rituximab-combined bi-weekly CHOP. Herein, we report that 13 of 90 (14%) patients developed IP during R-CHOP therapy, compared with none of 105 patients treated with CHOP alone as a historical control. There were no differences in baseline data between patients undergoing the two therapies. Among R-CHOP-treated patients, serum beta-D-glucan was increased in 8 of 12 (75%) IP patients compared with none of 30 non-IP patients examined. In five IP patients who underwent sputum evaluation, two were positive for P. jirovecii by the polymerase chain reaction and another two were positive for Candida albicans. No other organisms were detected as causative pathogens. Treatment with steroids, sulfamethoxazole-trimethoprim (ST), and antifungals was effective. Our results suggest that R-CHOP raises the incidence of IP, possibly through increasing the susceptibility to P. jirovecii and fungal infection. The need for prophylactic antifungals and ST during R-CHOP should be evaluated by randomized controlled trials.
Authors:
Daisuke Ennishi; Yasuhito Terui; Masahiro Yokoyama; Yuko Mishima; Shunji Takahashi; Kengo Takeuchi; Kazuma Ikeda; Mitsune Tanimoto; Kiyohiko Hatake
Related Documents :
7831539 - Community-acquired pneumonia: the future of the microbiology laboratory: focused diagno...
15906659 - Prevalence and clinical features of chlamydia pneumoniae pneumonia at srinagarind hospi...
2327729 - Low levels of unsaturated transferrin as a predictor of survival in pneumococcal pneumo...
19512939 - Bacterial meningitis in hiv-1-infected patients in the era of highly active antiretrovi...
19911359 - Pediatric parapneumonic pleural effusion: epidemiology, clinical characteristics, and m...
11964919 - Community-acquired pneumonia: process of care studies.
3808129 - Antiimmunoglobulins of rheumatoid factor (rf) type in prediction of melanoma patients.
19283229 - Overcoming communication barriers - working with patients with intellectual disabilities.
20028329 - Rapid sequence intubation: a review of recent evidences.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of hematology     Volume:  87     ISSN:  0925-5710     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-10-30     Completed Date:  2009-04-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  393-7     Citation Subset:  IM    
Affiliation:
Department of Oncology and Hematology, Cancer Institute Hospital, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biochemistry
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Female
Humans
Immunotherapy
Lung Diseases, Interstitial / metabolism,  pathology*
Lymphoma / drug therapy,  immunology
Male
Middle Aged
Prednisone / therapeutic use
Vincristine / therapeutic use
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/CHOP protocol; 0/rituximab; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics ...
Next Document:  Reserpine can confer stress tolerance and lifespan extension in the nematode C. elegans.